Liraglutide and Semaglutide are both GLP-1 receptor agonists, primarily studied for their roles in metabolic health. Evidence from our corpus suggests their utility in managing overweight and obesity, often in combination with exercise, leading to improvements in body composition and metabolic parameters. Both peptides have also shown promise in improving cardiovascular outcomes, particularly in obese individuals with ASCVD but without type 2 diabetes, and in providing cardiorenal protection in type 1 diabetes. Liraglutide has been evaluated for glycemic control in type 2 diabetes, while Semaglutide has been investigated for early Alzheimer's disease.
| Liraglutide | Semaglutide | |
|---|---|---|
| Drug class | glp 1 agonist | glp 1 agonist |
| Studies in corpus | 303 | 691 |
| Highest evidence tier | meta analysis | meta analysis |
| Evidence tier mix | rct · 69 cohort · 15 review · 21 meta analysis · 13 in vitro · 4 preclinical animal · 5 case series · 3 other · 30 case report · 1 | rct · 67 meta analysis · 9 review · 23 in vitro · 4 cohort · 16 preclinical animal · 4 case report · 3 case series · 3 other · 26 |
| Studies with explicit sample size | 43 | 42 |
| Head-to-head studies in corpus | 23 | |
Studies in our corpus that mention both Liraglutide and Semaglutide — the gold-standard direct comparison evidence.
This comprehensive meta-analysis suggests that current evidence does not consistently support GLP-1RAs as an effective treatment for motor or non-motor symptoms in Parkinson's disease. While the modest improvement in quality of life is a notable finding, it…
This systematic review provides compelling evidence that GLP1RAs offer a crucial therapeutic strategy for improving cardiovascular outcomes in a high-risk population previously less studied: obese individuals with ASCVD but without type 2 diabetes. This sug…
This comprehensive systematic review solidifies the evidence for GLP-1 RAs as crucial therapeutic agents for cardiovascular protection, extending their benefits far beyond glucose control and weight management. These robust findings strongly support the exp…
This comprehensive review provides crucial evidence for clinicians to make informed decisions when prescribing pharmacological interventions for weight management in non-diabetic adults. The significant weight loss observed with newer agents, particularly t…
A completed Phase 3 trial (NCT04074161) compared semaglutide 2.4 mg weekly to liraglutide 3.0 mg daily for weight management in overweight/obese adults over 68 weeks.
This study provides compelling real-world evidence that GLP-1 Receptor Agonist therapy offers substantial cardiorenal protection in Type 1 Diabetes patients, mirroring benefits previously observed in T2D. These findings suggest a critical expansion of GLP-1…
This study provides compelling preliminary evidence that semaglutide, a well-known GLP-1 receptor agonist, could be a highly effective and novel treatment for intractable diarrhea, offering a new therapeutic option for patients who have not responded to con…
The review highlights that GLP-1 RAs are highly effective for weight management and glycemic control, offering significant benefits for women with conditions like polycystic ovary syndrome (PCOS) or those at elevated risk for gestational diabetes. It unders…
This review underscores the critical role of pharmacotherapy in modern obesity management, moving beyond traditional lifestyle interventions alone. The significant weight loss and cardiovascular benefits demonstrated by newer agents like tirzepatide and sem…
No direct head-to-head trials in our corpus. Indirect comparison only. A completed Phase 3 trial (NCT04074161) compared semaglutide 2.4 mg weekly to liraglutide 3.0 mg daily for weight management over 68 weeks, suggesting a difference in dosing frequency and potential efficacy, though specific outcomes are not detailed in the summary. Semaglutide has also been studied in oral formulations, with a meta-analysis indicating that oral semaglutide 25 mg achieved exposure similar to subcutaneous 2.4 mg and led to greater weight loss in simulated studies. Liraglutide has been specifically explored for its efficacy in glycemic control against metformin monotherapy and metformin/glimepiride, and in combination with high-dose insulin for type 2 diabetes patients with severe insulin resistance. Semaglutide, on the other hand, has been investigated for potential links to non-arteritic anterior ischemic optic neuropathy risk and in phase 3 trials for early-stage symptomatic Alzheimer's disease.
Looking for vendor-level purity, endotoxin, and HPLC data on Liraglutide or Semaglutide? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.